Amgen and UCB re-file for Evenity approval in USA

13 July 2018

US biotech major Amgen (Nasdaq: AMGN) and Belgian pharma company UCB (Euronext Brussels: UCB) have resubmitted their Biologics License Application (BLA) to the US Food and Drug Administration for Evenity (romosozumab),

The drug is an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. The original Evenity BLA received a Complete Response Letter from the FDA a year ago, when the agency asked the companies to include in their application efficacy and safety data from the Phase III ARCH (Active-contRolled fraCture study in postmenopausal women with osteoporosis at High risk of fracture) trial, which compared Evenity to Merck & Co’s Fosamax(alendronate sodium). This study saw observation of a cardiovascular safety signal.

Market reaction to the news was muted, with Amgen closed up 0.49% at $194.09 yesterday, while UCB was down around 1% at 69.20 euros at lunch time today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK